Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy.
van der Doelen MJ, Mehra N, van Oort IM, Looijen-Salamon MG, Janssen MJR, Custers JAE, Slootbeek PHJ, Kroeze LI, Bruchertseifer F, Morgenstern A, Haberkorn U, Kratochwil C, Nagarajah J, Gerritsen WR. van der Doelen MJ, et al. Among authors: van oort im. Urol Oncol. 2021 Oct;39(10):729.e7-729.e16. doi: 10.1016/j.urolonc.2020.12.002. Epub 2021 Jan 11. Urol Oncol. 2021. PMID: 33353867 Free article.
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJ, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM. Badrising S, et al. Among authors: van oort im, van den eertwegh aj, van den berg hp, van tinteren h, van der noort v. Cancer. 2014 Apr 1;120(7):968-75. doi: 10.1002/cncr.28518. Epub 2013 Dec 30. Cancer. 2014. PMID: 24382803 Free article.
Self-reported acne is not associated with prostate cancer.
Cremers RG, Aben KK, Vermeulen SH, den Heijer M, van Oort IM, van de Kerkhof PC, Schalken JA, Kiemeney LA. Cremers RG, et al. Among authors: van oort im, van de kerkhof pc. Urol Oncol. 2014 Oct;32(7):941-5. doi: 10.1016/j.urolonc.2014.02.019. Epub 2014 Jul 8. Urol Oncol. 2014. PMID: 25011577
Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review.
Surcel CI, van Oort IM, Sooriakumaran P, Briganti A, De Visschere PJ, Fütterer JJ, Ghadjar P, Isbarn H, Ost P, van den Bergh RC, Yossepowitch O, Giannarini G, Ploussard G; Members of the Prostate Cancer Working Group of the Young Academic Urologists Working Party of the European Association of Urology. Surcel CI, et al. Among authors: van oort im, van den bergh rc. Urol Oncol. 2015 Jun;33(6):265.e1-7. doi: 10.1016/j.urolonc.2014.08.007. Epub 2014 Sep 17. Urol Oncol. 2015. PMID: 25238700 Review.
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H. Wissing MD, et al. Among authors: van oort im, van den eertwegh aj, van den berg p. Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231. Epub 2014 Oct 3. Int J Cancer. 2015. PMID: 25242736
172 results